Expert Interviews

Consequences of Delaying Intervention in Stage 2 T1D
December 10, 2024

Panelists discuss how delaying intervention in stage 2 type 1 diabetes, when dysglycemia is present but clinical symptoms have not yet developed, can lead to further ß-cell deterioration and worsen long-term glycemic control, ultimately increasing the risk of complications.

Examining the Stages of T1D Progression
December 10, 2024

Panelists discuss how the progression of type 1 diabetes unfolds through distinct stages, from the preclinical phase of autoimmunity to the onset of clinical diabetes, emphasizing the importance of early detection and intervention to improve patient outcomes.

Guidelines on Screening for T1D
December 10, 2024

Panelists discuss how adhering to screening guidelines for type 1 diabetes enables early detection and intervention, improving patient outcomes and delaying disease progression through timely treatments like teplizumab.

Assessing the Burden of T1D
December 10, 2024

Panelists discuss how managing the clinical, financial, and quality-of-life burdens of type 1 diabetes (T1D) requires early intervention, proactive care strategies, and the use of treatments like teplizumab to improve patient outcomes and reduce long-term complications.

New COVID-19 Vaccination Guidance for Older Adults & High-Risk Groups: A Conversation with NFID Medical Director Robert Hopkins, Jr, MD
December 09, 2024

Guidance from the Advisory Committee on Immunization Practices on best practices for COVID-19 vaccination continues to evolve, Hopkins explained.

Preventing Colon Cancer Before It Starts: Researchers Explore Novel Therapeutic Strategies
December 06, 2024

William Grady, MD, talks about the latest research in colorectal cancer, including treatments targeting senescent cells that contribute to tumor formation.

NFID Medical Director Highlights ACIP Rationale for Lowering Age for Pneumococcal Vaccination
December 06, 2024

Under risk-based guidelines, less than 30% of eligible adults are vaccinated against pneumococcal disease, said Robert Hopkins, Jr, MD. More details, here.

Antibody Screening for T1D
December 05, 2024

Panelists discuss how antibody screening for type 1 diabetes can identify at-risk individuals early, enabling proactive monitoring and intervention to delay or prevent disease onset.

Teplizumab Therapy to Delay Onset and Progression of T1D
December 05, 2024

Panelists discuss how teplizumab therapy can delay the onset and progression of type 1 diabetes (T1D) by preserving β-cell function and reducing the risk of developing full-blown diabetes in at-risk individuals.

Teplizumab Use in Practice
December 05, 2024

Panelists discuss clinical use of teplizumab including patient selection, navigating approval processes, and managing the 14-day infusion regimen to optimize outcomes and delay the progression of type 1 diabetes.